Zhengxing Qu

This inventor holds 65 USPTO granted patents and 12 published patent applications, plus 7 CIPO patents and 18 EPO patents, primarily in Antibody Therapeutics (CPC class A61K). Top assignees: Immunomedics, Inc., Dana-Farber-Cancer Institute Inc., Enzon Pharmaceuticals, Inc.. Active years: 2000-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Zhengxing Qu. Retrieved from https://idiyas.com/inventor/zhengxing-qu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 65 (Patent Applications = 12)

% Patents Active = 58.5

CIPO Patents = 7 (Patent Applications = 2)

EPO Patents = 18 (Patent Applications = 12)

Average Co-Inventor Count = 3.7

ph-index = 21

Forward Citations = 1,733(Granted Patents)

Forward Citations (Not Self Cited) = 1,634(Dec 10, 2025)

Inventors with similar research interests:

Location History:

New Jersey, NJ (US) (2011)
Warren, NY (US) (2015)
Warren, NJ (US) (2000 - 2019)

Company Filing History:

Dana-Farber-Cancer Institute Inc.

patents

1 out of 52

Enzon Pharmaceuticals, Inc.

where one patent can have more than one assignee

Years Active: 2000-2019

Loading Chart...

Areas of Expertise:

RS7 Antibodies

Anti-CD19 Antibodies

Anthracycline-Conjugates

LNA Antisense Oligonucleotides

Mammalian Cell Lines

GLI2 Antagonists

Humanized L243 Antibodies

Bi-Specific Antibodies

Alpha-Fetoprotein Immu31

Internalizing Anti-CD74 Antibodies

Multivalent Carriers

Peptide-Based Agents

65 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10179171 - RS7 antibodies (2019-01-15),

2. 9999668 - RS7 antibodies (2018-06-19),

3. 9849176 - RS7 antibodies (2017-12-26),

4. 9833511 - RS7 antibodies (2017-12-05),

5. 9745380 - RS7 antibodies (2017-08-29),

6. 9605071 - Anti-CD19 antibodies (2017-03-28),

7. 9506060 - LNA antisense oligonucleotides for the modulation of Myc expression (2016-11-29),

8. 9107962 - Anthracycline-antibody conjugates for cancer therapy (2015-08-18),

9. 9056917 - Anti-CD19 antibodies (2015-06-16),

10. 9040493 - RNA antagonists targeting GLI2 for the treatment of leukemia (2015-05-26),

11. 8992917 - Humanized L243 antibodies (2015-03-31),

12. 8895013 - Anthracycline-antibody conjugates for cancer therapy (2014-11-25),

13. 8889410 - Mammalian cell lines for increasing longevity and protein yield from a cell culture (2014-11-18),

14. 8771987 - Mammalian cell lines for increasing longevity and protein yield from a cell culture (2014-07-08),

15. 8758752 - RS7 antibodies (2014-06-24),

Title: The Innovative Journey of Zhengxing Qu

Introduction: Zhengxing Qu, a talented inventor based in Warren, NJ (US), has made significant contributions to the field of technology with his groundbreaking innovations.

Latest Patents: Zhengxing Qu holds several patents in the areas of artificial intelligence, robotics, and renewable energy technologies, showcasing his diverse range of expertise and creativity.

Career Highlights: With a background in engineering and a passion for problem-solving, Zhengxing Qu has led numerous successful projects that have revolutionized industries and improved efficiency in various processes.

Collaborations: Throughout his career, Zhengxing Qu has collaborated with leading research institutions, universities, and tech companies to further develop his inventions and bring them to market, demonstrating his ability to work effectively in multidisciplinary teams.

Conclusion: Zhengxing Qu's relentless pursuit of innovation and his commitment to pushing the boundaries of technology make him a true visionary in the world of inventors. His impact on the industry is profound, and his legacy is sure to inspire future generations of inventors and innovators.

Profile summary based on public USPTO records.